Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ICAAC Briefs: BioCryst Flu Candidate Rapivab, Melinta’s Delafloxacin For Gonorrhea And More

Executive Summary

The Interscience Conference on Antimicrobial Agents and Chemotherapy included presentations on Phase I study of delafloxacin for uncomplicated gonorrhea, Biocryst’s placebo-controlled flu trials of Rapivab and in vitro studies of Theravance’s Vibativ versus vancomycin.

You may also be interested in...



C Diff. Prevention Candidate Heads Into Clinic With Ambitious Timetable

Synthetic Biologics thinks it can produce first product to prevent C. difficile infections by protecting microbiome from impact of I.V. beta lactam antibiotics; biotech plans IND in next two months and hopes to produce proof-of-concept data within roughly one year.

Battling Infection: Hospitals Seek High-Tech Solutions

The market for diagnostic and infection control products will see continued growth as hospitals and other providers look to the technology sector to help fight the battle against health care-associated infections and antibiotic-resistant organisms.

Theravance Re-Introduces Vibativ In The U.S. Independently (For Now)

The biotech is bringing is long-plagued antibiotic back to U.S. patients, but is still searching for another company to help with commercialization efforts. Meanwhile, plans for its split and the launch of its partnered COPD drug are on track.

Topics

Related Companies

UsernamePublicRestriction

Register

ID001014

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel